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LUNASIN 
Definition 
Lunasin is a naturally-occurring peptide found in soybean and other plants with potent 
chemopreventive properties against different types of cancer.  
 
Characteristics  
Lunasin (from the Tagalog word “lunas” for cure) is a 43 amino-acid peptide initially 
identified in the soybean cotyledon (1). It corresponds to the small subunit peptide encoded 
within the soybean 2S albumin Gm2S-1 gene that also codes for a methionine-rich protein, a 
signal peptide, and a linker peptide. The sequence of lunasin 
1SKWQHQQDSCRKQLQGVNLTPC22-23EKHIMEKIQG32-33RGD35-DDDDDDDD43 (National 
Center for Biotechnology Information, NCBI, accession number AAP62458) is composed of 
four regions: fragment f(1-22) without any known function yet; f(23-32) targeting lunasin to 
chromatin; f(33-35) corresponding to RGD cell adhesion motif internalizing lunasin into the cell 
nucleus, and a continuous sequence f(35-43) of nine aspartic acid (D) residues responsible for 
lunasin’s direct binding to core histones.  
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Once identified in soybean, the presence of this peptide has been also demonstrated in 
other legumes such as lupin, plant species of the Solanaceae family, and cereals such as rye, 
barley, wheat, oat, triticale, and amaranth. Because of the absence of 2S albumins in cereals, 
recent studies have focused on elucidating the actual origin of lunasin, suggesting that this 
peptide is synthesized and secreted by microorganisms, either as a mature peptide or a precursor 
which is then processed by a microbial or endogenous plant proteinase.  
The chemopreventive properties of lunasin have been demonstrated in both in vitro and 
in vivo studies (2). First studies demonstrated that lunasin, in absence of carcinogens, seems not 
to affect neither cell morphology nor cell proliferation. However, when a transformation event 
occurs lunasin gets into action within the cell preventing induced-carcinogenic processes. At 
nanomolar concentrations, lunasin added exogenously significantly suppresses chemical-
carcinogen-induced (DMBA and MCA) foci formation in mouse fibroblasts cells C3H10T1/2 
(C3H). This effect is also produced by Lunasin in NIH3T3 cells, being 4-fold more effective (on 
a molar basis) than the Bowman-Birk inhibitor (BBI), a known cancer-preventive agent from 
soy. Lunasin also prevents transformation of mammalian cells by viral oncogenes. It inhibits, in 
a dose-dependent manner, foci formation in C3H cells and NIH3T3 cells transfected with the 
oncogene E1A, known to induce cell proliferation by inactivating the tumor suppressor 
retinoblastoma protein (Rb). Lunasin is effective even when added up to 15 days after 
transfection with E1A gene, suggesting its efficacy when applied even after the transformation 
event. Lunasin also suppresses colony formation induced by the ras-oncogene in MCF-7 cells 
stably transfected with an inducible form of the oncogene.  
Subsequent studies have proved that lunasin peptide also exerts anti-neoplastic effects in 
established cancer breast, colon, prostate, leukemia, and lymphoma cells lines. Moreover, efforts 
demonstrating the in vivo chemopreventive role of this peptide have been designed in chemical 
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carcinogen-induced and xenograft animal models. The effects of this peptide are exerted through 
modulating multiple cellular pathways implied in the stages of initiation, promotion and 
progression of cancer. In this line, several studies have reported that this peptide is able to 
modulate expression of different genes and proteins involved in former mentioned characteristics 
of tumor cells by controlling cell cycle, apoptosis, and signaling transduction. The ability of 
lunasin to arrest cell cycle at the S- and G2-M phases by increasing the levels of cyclin-
dependent kinases (CDK) inhibitors p15, p21 and p27, down-regulating the cyclins D1, D3, 
CDK4 and CDK6, and inhibiting the phosphorylation of retinoblastoma protein (Rb) has been 
demonstrated in transfected fibroblasts, and breast and colon cancer cells. High levels of two 
proliferation molecular biomarkers, Ki-67 and the proliferating cell nuclear antigen (PCNA) 
have been found in a variety of malignant cells lines, and have been markedly linked with the 
aggressiveness and growth capacities of the tumor. Intraperitoneal administration of lunasin in 
xenograft breast MDA-MB-231 and colorectal KM12L4 cancer liver metastasis mice models has 
been reported to suppress cell cycle progression through down-regulation of these two factors.  
Another mechanism by which lunasin exerts anti-neoplasic effects is through its 
apoptosis-inducing activity. In colon cancer HT-29 and KM12L4 cells, lunasin modulates the 
ratio between anti-apoptotic marker Bcl-2 and pro-apoptotic marker Bax, as well as regulates the 
activity of pro-apoptotic nuclear clusterin, cytochrome c, and caspase-3. In human breast cancer 
MCF-7 cells, lunasin has been found to increase the expression and protein levels of the tumor 
suppressor Phosphatase and tensin homolog (PTEN), and to enhance nuclear localization of 
that protein resulting in the induction of PTEN-mediated cellular apoptosis. Moreover, addition 
of lunasin to leukemia L1210 cells provoked a notable increase of caspase -8, -9, and -3 
activities. In breast cancer MDA-MB-231 cells, lunasin acts synergistically with both aspirin and 
anacardic acid increasing the percentage of early and late-apoptotic cells.  
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Histological analysis of stained tumor sections of xenograft MDA-MB-231 mice showed 
that lunasin-treated animals presented tumor destruction areas replaced by apoptotic and necrotic 
cells, and significantly higher levels of TUNEL-positive apoptotic cells. In addition, 
intraperitoneal injection of this peptide to colorectal cancer liver metastasis mice provoked a 
significant increase of the expression of the pro-apoptotic biomarker Bax, reduction of 
expression of the anti-apoptotic biomarker Bcl-2, and synergistic effects with oxaliplatin 
inducing apoptosis through modulation of the Bcl-2:Bax ratio.  
An epigenetic mode of action for lunasin has been suggested (Figure 1) (3), indicating 
that lunasin selectively kills cells that are being transformed by disrupting the dynamics of 
histone acetylation-deacetylation when a transforming event occurs. Under steady-state 
conditions in the cell, core histones H3 and H4 are mostly in a deacetylated (repressed) state, 
being the balance between histone acetylation-deacetylation a key cellular process linked to 
signal transduction pathways including those involved in cancer development. Beyond its 
internalization into the cell nucleus, biochemical evidence has shown that lunasin, both synthetic 
and naturally-extracted from plants, is able to bind to deacetylated histones inhibiting their 
acetylation. Moreover, lunasin has been found to inhibit the acetylation process in cells exposed 
to sodium butyrate, a known histone deacetylase inhibitor, and to compete with different histone 
acetyltransferases (HATs) such as PCAF, CBP/p300 and yGCN5. The tumor suppressor protein 
Rb functions by interacting with E2F promoter and recruiting histone deacetylases (HDAC) to 
keep the core histones in the deacetylated (repressed) state. The inactivation of Rb by the 
oncoprotein E1A dissociates the Rb-HDAC complex, exposing the deacetylated core histones to 
be acetylated by the action of HATs. When this event occurs, lunasin is triggered into action and 
binds to the deacetylated core histones, turning off transcription, which is perceived as abnormal 
by the cell and commits apoptosis. This epigenetic mechanism shows that lunasin can influence 
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regulatory pathways involving chromatin modifications that may be fundamental to carcinogenic 
pathways in general.  
Recently, antioxidant and anti-inflammatory properties of lunasin have been described 
which might contribute on its chemopreventive effects. In vitro, lunasin has been found to act as 
a potent scavenger of superoxide and peroxil radicals, inhibitor of linoleic acid oxidation and 
blocking agent of hydroxyl radical generation by chelating iron ferrous ions, protecting DNA 
from induced-oxidative damage. These antioxidant properties have been confirmed by cell 
culture models. The production of reactive oxygen species (ROS) has been reported to decrease 
in lipopolysaccharide (LPS)-induced RAW264.7 macrophages after treatment with lunasin. Also, 
this peptide is able to improve cell viability and decrease ROS levels in intestinal Caco-2 and 
liver HepG2 cells challenged by hydrogen peroxide and tert-butylhydroperoxide. In latter cells, 
lunasin also provokes depletion of reduced glutathione, modulation of glutathione peroxidase 
and catalase activities, decrease of carbonyl groups and recovery from cell death by restraining 
the caspase-3 apoptotic pathway.  
Lunasin has been also demonstrated to inhibit, in the LPS-induced RAW 264.7 murine 
macrophage cellular model, pro-inflammatory mediators such as interleukin (IL)-6, IL-1β, and 
tumor necrosis factor (TNF)-α by suppression of cyclooxygenase (COX)-2/prostaglandin (PG) 
E2, inducible nitric oxide synthase (iNOS)/nitric oxide (NO) and nuclear factor-kappa B (NF-κB) 
pathways. In this cell model, lunasin has been found to affect the expression of genes involved in 
cellular growth and proliferation, cellular function, cell to cell signaling, and cell cycle. 
Bioavailability is an important feature of an ideal cancer preventive agent. To exert this 
effect, once orally ingested, the peptides have to survive degradation by gastrointestinal and 
serum proteinases and peptidases, reaching the target tissue or organ in an active form. In vitro 
bioavailability studies simulating gastrointestinal digestion have demonstrated that lunasin, both 
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synthetic as well as purified from food is markedly hydrolyzed by pepsin and pancreatin; 
however, lunasin in foods has been shown to resist the action of these enzymes. Naturally 
present protease inhibitors in foods, such as BBI and Kunitz trypsin inhibitor (KTI), have been 
found to be major responsible for the lunasin’s protection against gastrointestinal enzymes. In 
vivo bioavailability studies carried out with animals and humans have also confirmed above in 
vitro findings. Lunasin is bioavailable after being orally administrated to mice and rats, being 
absorbed through gastrointestinal barrier and extensively distributed reaching different tissues 
such as liver, kidney, lung, mammary gland, prostate, and brain, where lunasin exerts its 
bioactive properties. In humans, an average of 4.5% absorption of lunasin from the total ingested 
in 50 g of soy protein has been reported.  
Recently, accumulating evidence has shown that lunasin not only executes a 
chemopreventive role and possesses inherent antioxidative, anti-inflammatory properties, but 
also is involved in cholesterol biosynthesis, and central nervous system and immune system 
regulation. Lunasin’s multiple bio-functions make it a promising peptide agent in the 
prevention/treatment of different disorders.  
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Figure 1.  
E1A-Rb-HDAC model to explain the ability of Lunasin to suppress E1A-induced transformation. 
Top diagram: Rb controls G1/S transcription by interacting with E2F promoter and recruiting 
HDAC to keep the core histones in the deacetylated (repressed) state. In a cell being 
transformed, E1A inactivates Rb and dissociates Rb-HDAC complex, exposing the deacetylated 
core histones in the E2F promoter (medium diagram). Lunasin competes with histone 
acetyltransferase (HAT) in binding to the deacetylated core histones. Bottom diagram: HAT 
binds and acetylates core histones, turning on E2F cell cycle transcription factors, leads to cell 
proliferation. Lunasin binds, turns off the transcription, perceived as abnormal by cell, results in 
apoptosis.     
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Cross-references 
Histones 
Highly alkaline proteins found in the nucleus of eukaryotic cells responsible for packaging and 
ordering the DNA into structural units called nucleosomes. They are the chief protein 
components of chromating, playing a crucial role in gene regulation. 
DMBA 
7,12-Dimethylbenz[a]anthracene. Polycyclic aromatic hydrocarbon with carcinogenic, 
tumorigenic and teratogenic effects. 
MCA 
3-methylcholanthrene. Polycyclic aromatic carcinogen compound often used to study the effects 
of anticancer compounds. 
Bowman-Birk inhibitor (BBI) 
Serine protease inhibitor consisting of a single chain of 71 amino acid residues cross-linked by 
seven pairs of disulfide bonds and a well characterized ability to inhibit trypsin and 
chymotrypsin. It has been shown to be capable of preventing or suppressing carcinogenic 
processes in a wide variety of in vitro and in vivo animal model systems. 
Retinoblastoma protein 
Tumor suppressor protein belonging to the pocket protein family whose members have a pocket 
for the functional binding of other proteins. One of its major functions is the prevention of 
excessive cell growth by inhibiting cell cycle progression until the cell is ready to divide. When 
the cell is ready, Rb is phosphoryltated, becoming inactive, thus allowing cell cycle progression. 
It also acts as a recruiter of several chromatin remodeling enzymes such as methylases and 
acetylases.   
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Cyclin-dependent kinases (CDK) 
Family of protein kinases with molecular weights ranged from 34 to 40 kDa, present in all know 
eukaryotics, that bind a regulatory protein called cyclin. They are involved in the regulation of 
cell cycle, transcription, mRNA processing and differentiation of nerve cells.  
Cyclins 
Family of proteins that control the progression of cells through the cell cycle by activating CDK 
enzymes.  
Phosphatase and tensin homolog (PTEN) 
Human phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase encoded by the PTEN gene. It 
negatively regulates intracellular levels of phosphatidylinositol-3,4,5-triphosphate in cells and 
functions as a tumor suppressor by negatively regulating Akt/PKB signaling pathway. 
Epigenetic 
Study, in the field of genetics, of cellular and phenotypical variations caused by external or 
environmental factors that switch genes on and off affecting the mode how cells “read” genes. 
Epigenetic research describes dynamic alterations in the transcriptional potential of a cell. 
Histone acetyltransferases (HATs) 
Family of proteins that acetylate conserved lysine amino acids on histone proteins by transferring 
an acetyl group from acetyl CoA to lysine to form ε-N-acetyl lysine. Lysine acetylation 
neutralizes the positive charge normally present, thus reducing affinity between histone and 
(negatively charged) DNA which renders DNA more accessible to transcription factors. Also, 
histone acetylation and other posttranslational modifications generate binding sites for specific 
protein-protein interaction domains.  
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Kunitz Trypsin inhibitor (KTI) 
Antinutritional/allergen protein found in soybean that acts as an inhibitor of pancreatin and 
chymotrypsin. 
 
 
 
